Abstract
Metabolic dysregulation is a hallmark of neurodegenerative diseases, including Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). While metabolic dysregulation is a common link between these two tauopathies, a comprehensive brain metabolic comparison of the diseases has not yet been performed. We analyzed 342 postmortem brain samples from the Mayo Clinic Brain Bank and examined 658 metabolites in the cerebellar cortex and the temporal cortex between the two tauopathies. Our findings indicate that both diseases display oxidative stress associated with lipid metabolism, mitochondrial dysfunction linked to lysine metabolism, and an indication of tau-induced polyamine stress response. However, specific to AD, we detected glutathione-related neuroinflammation, deregulations of enzymes tied to purines, and cognitive deficits associated with vitamin B. Taken together, our findings underscore vast alterations in the brain’s metabolome, illuminating shared neurodegenerative pathways and disease-specific traits in AD and PSP.
Competing Interest Statement
R.K.D., MArnold, GK are (through their institutions) inventors on key patents in the field of metabolomics, including applications for Alzheimers disease. R.K.D. holds equity in Metabolon Inc., a metabolomics technologies company. This platform was used in the current analyses. R.K.D. formed Chymia LLC and PsyProtix, a Duke University biotechnology spinout aiming to transform the treatment of mental health disorders. MArnold and GK hold equity in Chymia LLC and IP in PsyProtix. JK holds equity in Chymia LLC and IP in PsyProtix and is cofounder of iollo.
Funding Statement
We thank the patients and families for their participation, without whom these studies would not have been possible. This work was done as part of the National Institute of Agings Accelerating Medicines Partnership for AD (AMP.AD) and was supported by NIH grants 1U19AG063744, 1R01AG069901 01A1, U01AG061357, P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, U01AG61356, RF1AG058942, RF1AG059093, and U01AG061359. The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org). The Mayo Clinic samples are part of the RNAseq study data led by Dr. Niluefer Ertekin Taner, Mayo Clinic, Jacksonville, FL as part of the multi PI U01 AG046139 (MPIs Golde, Ertekin-Taner, Younkin, Price). Samples were provided from the following sources: The Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. Study data includes samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimers Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimers Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinsons Disease Consortium) and the Michael J. Fox Foundation for Parkinsons Research. RB is also supported by Alzheimers association award AARFD 22 974775. RB thanks her colleagues from the Krumsiek lab for fruitful discussions and support in this work. NET, XW and MA are supported by R01AG061796, U01AG046139 and U19AG074879. NET is also supported by the Alzheimers Association Zenith Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the appropriate Mayo Clinic Institutional Review Board. All participants or next-of-kin provided consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Metabolomics as well as clinical data for the Mayo Clinic cohorts are available via the AD Knowledge Portal. The AD Knowledge Portal is a platform for accessing data, analyses, and tools generated by the Accelerating Medicines Partnership (AMP-AD) Target Discovery Program and other National Institute on Aging (NIA)-supported programs to enable open-science practices and accelerate translational learning. The data, analyses, and tools are shared early in the research cycle without a publication embargo on a secondary use. Data is available for general research use according to the following requirements for data access and data attribution (https://adknowledgeportal.org/DataAccess/Instructions). For access to the metabolomics data used in this manuscript see: https://www.synapse.org/#!Synapse:syn26446587
An interactive view of AD associations from this study can be found at https://krumsieklab.shinyapps.io/tauopathies/
All R scripts to generate the tables and figures of this paper are available at https://github.com/krumsieklab/ad-mayo-tauopathies
